| Definition of treatment goals for moderate to severe psoriasis: a European consensus U Mrowietz, K Kragballe, K Reich, P Spuls, CEM Griffiths, A Nast, J Franke, ... Archives of dermatological research 303, 1-10, 2011 | 1133 | 2011 |
| European S3‐Guidelines on the systemic treatment of psoriasis vulgaris–Update 2015–Short version–EDF in cooperation with EADV and IPC A Nast, P Gisondi, AD Ormerod, P Saiag, C Smith, PI Spuls, P Arenberger, ... Journal of the European Academy of Dermatology and Venereology 29 (12), 2277 …, 2015 | 543 | 2015 |
| Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies JMGR de Morales, L Puig, E Daudén, JD Cañete, JL Pablos, AO Martín, ... Autoimmunity reviews 19 (1), 102429, 2020 | 282 | 2020 |
| High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without psoriatic arthritis: a prospective case–control study E Naredo, I Möller, E de Miguel, E Batlle-Gualda, C Acebes, E Brito, ... Rheumatology 50 (10), 1838-1848, 2011 | 271 | 2011 |
| Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials I Garcia-Doval, G Carretero, F Vanaclocha, C Ferrandiz, E Daudén, ... Archives of dermatology 148 (4), 463-470, 2012 | 204 | 2012 |
| The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics E Christophers, J Barker, CEM Griffiths, E Daudén, G Milligan, C Molta, ... Journal of the European Academy of Dermatology and Venereology 24 (5), 548-554, 2010 | 195 | 2010 |
| Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study VCY Ho, CEM Griffiths, J Berth-Jones, KA Papp, F Vanaclocha, E Dauden, ... Journal of the American Academy of Dermatology 44 (4), 643-651, 2001 | 182 | 2001 |
| Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study SK Mahil, N Dand, KJ Mason, ZZN Yiu, T Tsakok, F Meynell, B Coker, ... Journal of allergy and clinical immunology 147 (1), 60-71, 2021 | 173 | 2021 |
| Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis E Daudén, S Castañeda, C Suárez, J García‐Campayo, AJ Blasco, ... Journal of the European Academy of Dermatology and Venereology 27 (11), 1387 …, 2013 | 173 | 2013 |
| Targeting miR-21 to Treat Psoriasis J Guinea-Viniegra, M Jiménez, HB Schonthaler, R Navarro, Y Delgado, ... Science translational medicine 6 (225), 225re1-225re1, 2014 | 163 | 2014 |
| European S3-Guideline on the systemic treatment of psoriasis vulgaris-Update Apremilast and Secukinumab-EDF in cooperation with EADV and IPC. A Nast, PI Spuls, G Kraaij, P Gisondi, C Paul, AD Ormerod, P Saiag, ... Journal of the European Academy of Dermatology & Venereology 31 (12), 2017 | 146 | 2017 |
| A novel circulating noncoding small RNA for the detection of acute myocarditis R Blanco-Domínguez, R Sánchez-Díaz, H de la Fuente, ... New England Journal of Medicine 384 (21), 2014-2027, 2021 | 139 | 2021 |
| Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. E Dauden, CEM Griffiths, JP Ortonne, K Kragballe, CT Molta, D Robertson, ... Journal of the European Academy of Dermatology & Venereology 23 (12), 2009 | 125 | 2009 |
| Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study … R Navarro, E Vilarrasa, P Herranz, L Puig, X Bordas, JM Carrascosa, ... British Journal of Dermatology 168 (3), 609-616, 2013 | 122 | 2013 |
| Consensus document on the evaluation and treatment of moderate‐to‐severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology E Daudén, L Puig, C Ferrándiz, JL Sánchez‐Carazo, ... Journal of the European Academy of Dermatology and Venereology 30, 1-18, 2016 | 121 | 2016 |
| Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM registry P Dávila-Seijo, E Dauden, MA Descalzo, G Carretero, JM Carrascosa, ... Journal of Investigative Dermatology 137 (2), 313-321, 2017 | 118 | 2017 |
| Integrated approach to comorbidity in patients with psoriasis E Daudén, S Castañeda, C Suárez, J García-Campayo, AJ Blasco, ... Actas Dermo-Sifiliográficas (English Edition) 103, 1-64, 2012 | 112 | 2012 |
| Psoriasis y depresión: el papel de la inflamación S González-Parra, E Daudén Actas dermo-sifiliograficas 110 (1), 12-19, 2019 | 103 | 2019 |
| Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis P Dávila‐Seijo, E Dauden, G Carretero, C Ferrandiz, F Vanaclocha, ... Journal of the European Academy of Dermatology and Venereology 30 (11), 1942 …, 2016 | 103 | 2016 |
| CD69 controls the uptake of L-tryptophan through LAT1-CD98 and AhR-dependent secretion of IL-22 in psoriasis D Cibrian, ML Saiz, H de la Fuente, R Sánchez-Díaz, O Moreno-Gonzalo, ... Nature immunology 17 (8), 985-996, 2016 | 102 | 2016 |
